Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/08/2005WO2005077932A3 Chemokine receptor antagonists
12/08/2005WO2005077356A3 Glycine and/or for use in cartilage affecting conditions
12/08/2005WO2005075436A3 Novel inhibitors of glutaminyl cyclase
12/08/2005WO2005074925A8 Compositions substantially free of galactomannan containing piperacillin and tazobactam
12/08/2005WO2005074884A3 Sustained release pharmaceutical composition of indapamide
12/08/2005WO2005072713A3 Cholinesterase inhibitors for treating inflammation
12/08/2005WO2005070461A3 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
12/08/2005WO2005067936A3 Methods for the production of sildenafil base and citrate salt
12/08/2005WO2005065648A3 Novel drug compositions and dosage forms of topiramate
12/08/2005WO2005065646A3 Novel drug compositions and dosage forms
12/08/2005WO2005065640A8 Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
12/08/2005WO2005065308A3 Compositions and methods to treat recurrent medical conditions
12/08/2005WO2005062894A3 Co-administration of dopamine-receptor binding compounds
12/08/2005WO2005060654A3 Mitotic kinesin inhibitors
12/08/2005WO2005058341A3 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
12/08/2005WO2005058298B1 Fk228 analogs and their use as hdac-inhibitors
12/08/2005WO2005055951A3 Methods and compositions for slowing aging
12/08/2005WO2005054432A3 Gene transfer for regulating smooth muscle tone
12/08/2005WO2005046797B1 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
12/08/2005WO2005046726A3 Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
12/08/2005WO2005044190A3 Compositions and methods for treatment of nervous system disorders
12/08/2005WO2005041881A3 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
12/08/2005WO2005040111A3 Combinatorial library of 3-aryl-1h-indole-2-carboxylic acids
12/08/2005WO2005034940A3 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases
12/08/2005WO2005034873A3 A method for reducing anti-neoplastic agent induced side-effects
12/08/2005WO2005032452A3 Alkyl-substituted pcdf as a treatment for prostate cancer
12/08/2005WO2005030149A3 Suppression of hiv replication for prevention and treatment of hiv
12/08/2005WO2005027977A3 Diclofenac compositions for the treatment of skin disorders
12/08/2005WO2005018555A3 Lipid-modified immune response modifiers
12/08/2005WO2005011578A2 Preoperative treatment of post operative pain
12/08/2005WO2005009951A3 Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
12/08/2005WO2005009384A3 Egfr tyrosine kinase inhibitors
12/08/2005WO2005009383A3 Methods of treatment with lxr agonists
12/08/2005WO2004100935A3 Propofol formulation containing reduced oil and surfactants
12/08/2005WO2004096139A8 Aza spiro alkane derivatives as inhibitors of metalloproteases
12/08/2005WO2004093805A3 Selective spirocyclic glucocorticoid receptor modulators
12/08/2005WO2004093798A3 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
12/08/2005WO2004085582A8 Lipid-improving agent and composition containing lipid-improving agent
12/08/2005WO2004078682A3 Cyclic compounds and compositions as protein kinase inhibitors
12/08/2005WO2004069173A3 Methods for modulating an inflammatory response
12/08/2005WO2004066912A3 Anti-inflammatory compositions and uses thereof
12/08/2005WO2004058042A3 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases
12/08/2005WO2004056315A8 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/08/2005WO2003065982A3 Engineering absorption of therapeutic compounds via colonic transporters
12/08/2005WO2003032895A3 Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
12/08/2005WO2002057256A9 Piperazinylcarbonylquinolines and -isoquinolines
12/08/2005US20050273047 System and method for transdermal delivery of an anticoagulant
12/08/2005US20050272955 Substituted cyclopentene compounds
12/08/2005US20050272943 Process for preparing prostaglandin derivatives and starting materials for the same
12/08/2005US20050272936 Imidazolium cxcr3 inhibitors
12/08/2005US20050272931 Vanilloid receptor ligands and their use in treatments
12/08/2005US20050272921 Process for producing glycoside
12/08/2005US20050272825 Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
12/08/2005US20050272824 Methods for monitoring combretastatin resistance
12/08/2005US20050272823 improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines
12/08/2005US20050272822 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
12/08/2005US20050272821 Levalbuterol hydrochloride Polymorph A
12/08/2005US20050272820 Nontoxic killer of E. coli and other problem microorganisms
12/08/2005US20050272819 Use of alkylureas for treating acne
12/08/2005US20050272818 Novel process for producing Ibuprofen sodium dihydrate
12/08/2005US20050272817 Dermatological use and a dermatological preparation
12/08/2005US20050272816 3,5,3' -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
12/08/2005US20050272815 Compounds and compositions for delivering active agents
12/08/2005US20050272814 Medicine for prevention or treatment of diabetes
12/08/2005US20050272813 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
12/08/2005US20050272812 Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
12/08/2005US20050272810 Compositions comprising nebivolol
12/08/2005US20050272808 Compositions and methods for the treatment of hypertension
12/08/2005US20050272806 Injectable formulations of taxanes for cad treatment
12/08/2005US20050272805 Treatment of gastrointestinal disorders with duloxetine
12/08/2005US20050272804 Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
12/08/2005US20050272803 Phosphodiesterase 4 inhibitors
12/08/2005US20050272802 Process for preparing form I of tegaserod maleate
12/08/2005US20050272801 Isoprenoid pathway inhibitors for stimulating cartilage growth
12/08/2005US20050272800 NK1 antagonists
12/08/2005US20050272799 Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
12/08/2005US20050272798 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents
12/08/2005US20050272796 Prevention and treatment of benign prostatic hyperplasia using lonidamine and lonidamine analogs
12/08/2005US20050272795 Prevention and treatment of benign prostatic hyperplasia
12/08/2005US20050272794 Pyrazole derivatives, compositions containing such compounds and methods of use
12/08/2005US20050272793 Pyrazole compounds and uses related thereto
12/08/2005US20050272792 Benzimidazoles, process for their preparation and use thereof as medicament
12/08/2005US20050272791 Lung melanoma metastasis, rheumatoid arthritis, 1-isopropylsulfonyl-2-amino-6-(2-(2,6-difluorophenyl)-5-(phenyl)-imidazol-4-yl)-benzimidazole
12/08/2005US20050272790 Galenic formulations of organic compounds
12/08/2005US20050272789 Triazole-derived kinase inhibitors and uses thereof
12/08/2005US20050272788 Indoles having anti-diabetic activity
12/08/2005US20050272787 Process for preparing crystalline form A of valdecoxib
12/08/2005US20050272784 Inhibitors of bacterial Type III protein secretion systems
12/08/2005US20050272783 Amino acids with affinity for the alpha2delta-protein
12/08/2005US20050272782 such as [(2-methoxyphenyl)-(1-methyl-5-piperidin-1-ylmethyl-1H-pyrrol-2-yl)-methyl]-dimethylamine, exhibiting an elevated affinity for opioid receptors and as selective serotonin reuptake inhibitors, used as analgesics and for the treatment of drug abuse, neurodegenerative and cardiovascular disorders
12/08/2005US20050272781 Protecting the hydroxyls of 3-hydroxy-4,5-dimethylol-2-picoline, reacting the 4-methylol group with an imide (especially potasssium phthalimide), cleaving the imide group to deprotect the amine group, and deprotecting the remaining hydroxy groups; post-Amadori advanced glycation end-products.
12/08/2005US20050272780 Small molecule inhibitors of rotamase enzyme activity
12/08/2005US20050272779 2-[5-(3-Methoxy-phenyl)-[1,2,4]oxadiazol-3-ylmethylsulfanyl]-1H-benzoimidazole, for example; useful for the inhibition of transient lower esophageal sphincter relaxations and thus for treatment of gastro-esophageal reflux disorder
12/08/2005US20050272778 Inhibitors of proteins that bind phosphorylated molecules
12/08/2005US20050272776 Compositions containing opioid antagonist
12/08/2005US20050272775 Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
12/08/2005US20050272774 Substituted cyclohexane derivatives
12/08/2005US20050272773 Use of R (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition
12/08/2005US20050272772 Pharmaceutical compositions for the treatment of pruritus
12/08/2005US20050272771 Such as terfenadine carboxylic acid metabolite and carebastine using a 4-(4-halo-1-oxobutyl)-alpha,alpha-dimethyl-alpha-substituted toluene intermediate
1 ... 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 ... 7860